Welcome to our dedicated page for Fulcrum Therapeutics news (Ticker: FULC), a resource for investors and traders seeking the latest updates and insights on Fulcrum Therapeutics stock.
Fulcrum Therapeutics, Inc. reports developments as a clinical-stage biopharmaceutical company developing small-molecule therapies for genetically defined rare diseases and rare hematological disorders. Its lead clinical program, pociredir, is designed to increase fetal hemoglobin for the treatment of sickle cell disease, and company updates commonly address PIONEER trial data, markers of hemolysis and anemia, and sickle cell disease collaborations.
FULC news also covers quarterly financial results, corporate presentations, Nasdaq inducement equity grants, board composition, and updates to the company's pipeline and financial position as it advances small molecules that modulate gene expression.
Fulcrum Therapeutics (Nasdaq: FULC) announced the granting of stock options to two new employees as part of its 2022 Inducement Stock Incentive Plan. A total of 113,200 shares were granted at an exercise price of $12.41 each, reflecting the closing price on February 6, 2022. The options have a ten-year term and will vest over four years, beginning with 25% vesting after the first year and 6.25% quarterly thereafter. Fulcrum Therapeutics is focused on developing treatments for genetically defined rare diseases, with lead programs targeting facioscapulohumeral muscular dystrophy and sickle cell disease.
Fulcrum Therapeutics (Nasdaq: FULC) announced management's participation in the virtual SVB Securities Global Biopharma Conference on February 15, 2023, at 10:00 AM ET. The presentation will be accessible via webcast on the company's website, with an archived replay available for 90 days. Fulcrum is dedicated to enhancing the lives of patients with genetically defined rare diseases, focusing on two lead programs: losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 for sickle cell disease and other hemoglobinopathies. Their proprietary FulcrumSeek™ engine targets gene expression to tackle underlying genetic issues.
Fulcrum Therapeutics (FULC) announced a public offering of 9,615,384 common shares priced at $13.00 each, aiming to raise approximately $125 million before expenses. This offering is conducted under an existing shelf registration statement and is expected to close on or about January 20, 2023. The underwriters have a 30-day option to purchase an additional 1,442,307 shares. Goldman Sachs, SVB Securities, and Piper Sandler are managing the offering. The funds are aimed at advancing Fulcrum’s clinical programs targeting genetic rare diseases, specifically treatments for facioscapulohumeral muscular dystrophy and sickle cell disease.
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) has announced a public offering of $100 million in common stock, with an additional $15 million available to underwriters. The offering, led by Goldman Sachs & Co. LLC, SVB Securities, and Piper Sandler & Co., aims to support the company’s focus on genetically defined rare diseases. The shares will be offered under an effective shelf registration statement previously filed with the SEC. Completion of the offering is contingent on market conditions, with no assurance on final terms.
Fulcrum Therapeutics (Nasdaq: FULC) announced the grant of non-statutory stock options to new employees under its 2022 Inducement Stock Incentive Plan. A total of 29,200 options were awarded to two employees at an exercise price of $10.20 per share, reflecting the closing price on January 9, 2023. The options vest over four years, with 25% vesting after one year and the remaining 75% in quarterly installments over the next three years, contingent on continued employment. Fulcrum focuses on treating genetically defined rare diseases, with clinical programs targeting facioscapulohumeral muscular dystrophy and sickle cell disease.
Fulcrum Therapeutics (Nasdaq: FULC) provided updates on its clinical programs and corporate changes. The FDA granted Fast Track Designation to FTX-6058 for sickle cell disease, with promising Phase 1b trial results showing up to 9.5% increases in fetal hemoglobin (HbF). Enrollment continues in the ongoing trials for both FTX-6058 and losmapimod, targeted for facioscapulohumeral muscular dystrophy. The company also announced a leadership change, appointing Robert J. Gould as interim CEO. Fulcrum expects sufficient cash runway to fund operations into late 2024.
Fulcrum Therapeutics has appointed Robert J. Gould, Ph.D. as interim CEO following the departure of Bryan Stuart to pursue other opportunities. This transition, effective January 3, 2023, comes as the company seeks a permanent CEO. Gould, a founding member and former CEO, brings over 35 years of industry experience and will guide the company through ongoing clinical programs, including FTX-6058 for sickle cell disease and losmapimod for facioscapulohumeral muscular dystrophy. The Board expressed confidence in Gould's leadership during this pivotal time.
Fulcrum Therapeutics (Nasdaq: FULC) announced the granting of 400,000 stock options to four new employees as part of its 2022 Inducement Stock Incentive Plan. The options include 250,000 shares at an exercise price of $6.55 and 150,000 shares at $6.56, aligned with the closing prices of the Company’s stock on respective grant dates. Each option has a ten-year term and vests over four years, promoting employee retention and performance. Fulcrum focuses on treating genetically defined rare diseases, with lead programs targeting muscular dystrophy and sickle cell disease.
Fulcrum Therapeutics (Nasdaq: FULC) will participate in a virtual fireside chat at the 2022 BofA Securities Biotech SMID Cap Conference on December 8, 2022, at 9:10 a.m. ET. The event aims to provide insights into the company's initiatives focused on genetically defined rare diseases. A live audio webcast will be accessible on the Fulcrum website, with an archived replay available for 30 days after the event. Fulcrum is advancing two key clinical programs: losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 for sickle cell disease.
Fulcrum Therapeutics (Nasdaq: FULC) announced the granting of non-statutory stock options totaling 478,820 shares to four new employees, including 400,000 shares to Santiago Arroyo, M.D., Ph.D., the new Chief Medical Officer. The options, priced at $5.61 per share, are part of the 2022 Inducement Stock Incentive Plan and include a ten-year term with vesting over four years. Fulcrum is dedicated to addressing genetically defined rare diseases, focusing on advancing its lead drugs for facioscapulohumeral muscular dystrophy and sickle cell disease.